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Abstract 
Background: We compared the risk of bleeding and cardiovascular disease (CVD) events between non-vitamin K 
antagonist oral anticoagulant (NOAC) and warfarin in people with type 2 diabetes (T2DM).
Methods: 862 Incident NOAC users and 626 incident warfarin users with T2DM were identified from within 40 
UK general practice (1/4/2017–30/9/2018). Outcomes included incident hospitalisation for bleeding, CVD and re-
hospitalisation for CVD within 12 months since first anticoagulant prescription, identified from linked hospitalisation 
data. A tapered matching method was applied to form comparison cohorts: coarsened exact matching restricted the 
comparison to areas of sufficient overlap in missingness and characteristics: (i) demographic characteristics; (ii) clinical 
measurements; (iii) prior bleeding and CVD history; (iv) prescriptions with bleeding; (v) anti-hypertensive treatment(s); 
(vi) anti-diabetes treatment(s). Entropy balancing sequentially balanced NOAC and warfarin users on their distribu-
tion of (i–vi). Weighted logistic regression modelling estimated outcome odds ratios (ORs), using entropy balancing 
weights from steps i–vi.
Results: The 12-month ORs of bleeding with NOAC (n = 582) vs matched/balanced warfarin (n = 486) were 1.93 (95% 
confidence interval 0.97–3.84), 2.14 (1.03–4.44), 2.31 (1.10–4.85), 2.42 (1.14–5.14), 2.41 (1.12–5.18), and 2.51 (1.17–5.38) 
through steps i–vi. ORs for CVD re-hospitalisation was increased with NOAC treatment through steps i–vi: 2.21 
(1.04–4.68), 2.13 (1.01–4.52), 2.47 (1.08–5.62), 2.46 (1.02–5.94), 2.51 (1.01–6.20), and 2.66 (1.02–6.94).
Conclusions: Incident NOAC use among T2DM is associated with increased risk of bleeding hospitalisation and CVD 
re-hospitalisation compared with incident warfarin use. For T2DM, caution is required in prescribing NOACs as first 
anticoagulant treatment. Further large-scale replication studies in external datasets are warranted.
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Background
Anticoagulants are used for the prevention and treat-
ment of venous thromboembolism and to reduce the risk 
of stroke in patients with either atrial fibrillation or after 
acute pulmonary embolism, deep vein thrombosis [1, 2]. 
Warfarin has been used for six decades but in the last 
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8 years its use has been gradually replaced by non-vita-
min K antagonist oral anticoagulants (NOACs) including 
dabigatran, rivaroxaban, and apixaban. Unlike warfarin, 
these drugs have set doses and do not generally require 
regular international normalisation ratio blood test 
monitoring [3]. They also have faster onset and offset of 
action. There are, however, some concerns regarding the 
safety of NOACs with respect to bleeding because there 
is a limited choice of antidotes, experience with rever-
sal agents is limited outside of trials and some remain 
expensive [4, 5].
Studies in the general population have reported poten-
tial further clinical benefits of NOACs over warfarin, for 
example, QResearch found potential for apixaban to be 
associated with a decreased risk of major bleeding events 
in patients with and without atrial fibrillation compared 
with warfarin; rivaroxaban is associated with a decreased 
risk of intracranial bleeding in patients without atrial 
fibrillation compared with warfarin; rivaroxaban and 
low dose apixaban are associated with an increased risk 
of all-cause mortality in patients with and without atrial 
fibrillation compared to warfarin [6]. However, few 
observational cohort studies have addressed short-term 
outcomes such as hospitalisation due to bleeding and 
cardiovascular disease (CVD), which are linked to sig-
nificant health costs [7, 8]. Moreover, few studies have 
examined such associations in populations with type 2 
diabetes, which is distinctively different from the general 
population, in terms of age, and comorbidities [9].
To compare the risks of major bleeding and CVD hos-
pitalisation between incident NOAC and warfarin users 
with type 2 diabetes, we have used a recently intro-
duced statistical approach: tapered multivariable match-
ing [10, 11]. This allows us to examine the extent of the 
observed difference in these outcomes between NOAC 
and warfarin users, and more importantly to investigate 
how potential confounders relate to the risk differentia-
tion. In tapered matching, we sequentially match NOAC 
user group to the warfarin user group with an increas-
ingly comprehensive set of variables. As we incremen-
tally match the NOAC user group and the warfarin user 
group, we can directly observe how the matched cohorts 
change both in terms of risk of outcome and in terms of 
unmatched covariables.
Methods
Data sources
Two UK primary care databases from two clinical com-
missioning groups (CCGs) in England were used for 
this study. All 21 practices in CCG-1 and 19 practices 
in CCG-2 practices were linked at the patient level to 
hospital admission data (Secondary User Service (SUS) 
data). We used READ codes to extract the information 
from general practices [12, 13] and ICD-10 (international 
classification of diseases, 10th revision) codes for out-
comes extracted from SUS data (codes list is accessible 
by reasonable request via corresponding author) [14, 15]. 
Anonymised data were used in this study. The study was 
approved by South West—Exeter Research Ethics Com-
mittee (REC reference: 17/SW/0001).
The study period ran from 1 January 2017 to 30 Sep-
tember 2018. All patients with type 2 diabetes newly 
prescribed the oral anticoagulants warfarin, dabigatran, 
rivaroxaban, and apixaban, and aged from 18 to 99 years 
at the date of study entry, were eligible to be enrolled 
in this study. The entry date was defined as the date of 
the first prescription of any of the anticoagulant drugs. 
To facilitate a direct comparison between new users of 
NOACs against new users of warfarin, and to reduce 
the impact of indication bias, patients were excluded 
if they had any anticoagulant prescription in the prior 
12  months before the entry date. To ensure the quality 
of data, patients were also excluded if they had less than 
12  months of registration history before entry. Interna-
tional Normalized Ratio (INR) monitoring was consid-
ered a key component of warfarin management and as 
such included in the term “warfarin use”. INR informa-
tion was not available in this study.
The outcome of interest included (i) incident hospitali-
sation due to CVD defined by the primary ICD-10 code 
within the 12  months following the first anticoagulant 
prescription; (ii) incident hospitalisation mainly due to 
bleeding events defined by the primary ICD-10 codes 
within the 12  months since the first anticoagulant pre-
scription; (iii) re-hospitalisation mainly due to CVD (hav-
ing ≥ 2 hospitalisations mainly due to CVD) defined by 
the primary ICD-10 codes within the 12  months since 
the first anticoagulant prescription. It is important to 
note that other conditions defined by non-primary ICD-
10 codes could have contributed to the hospitalisation, 
but these have not been used in the definition of the 
outcomes.
Patients were followed from their first prescription 
of an anticoagulant until they experienced an outcome 
of interest or by the 12  months without experiencing 
any outcome of interest. Patients were excluded if they 
stopped or suspended treatment up to 30 days after the 
first anticoagulant prescription. Patients were excluded 
if they switched between NOAC and warfarin within the 
first 12 months.
Statistical methods
Matching method
This study used a tapered matching method to generate 
a series of matches for each comparison of NOAC and 
warfarin [16]. For the NOAC user group, we performed 
Page 3 of 10Yu et al. Cardiovasc Diabetol          (2020) 19:174  
six matches that constructed sets of pairs of warfarin 
users as shown in Fig.  1. First, demographic factors 
match paired patients by their age at incident antico-
agulant prescription, gender, the CCG associated with 
their practice, duration of recorded diagnosed type 
2 diabetes by their incident anticoagulant prescrip-
tion, and issue year of incident anticoagulant prescrip-
tion. Second, the NOAC user group match controlled 
(warfarin user group) for all demographic factors and 
clinical measurements (body mass index, systolic 
Fig. 1 Workflow charts for matching process
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blood pressure, HbA1c and total cholesterol). Third, 
the NOAC user group were matched with the warfa-
rin user group for all variables in the first 2 matches 
as well as prior bleeding (gastrointestinal bleeding and 
other bleeding) and CVD subtypes (hypertension, atrial 
fibrillation, heart failure, ischemic heart disease, cer-
ebrovascular diseases, valvular heart disease, venous 
thrombosis); Fourth, the NOAC user group were 
matched with the warfarin user group for all variables 
in the first 3 matches as well as prescriptions poten-
tially relevant to bleeding event (antidepressant, Sta-
tin, NSAIDS, Corticosteroid, proton pump inhibitor 
for gastrointestinal disease, and antiplatelet). Fifth, the 
NOAC user group were matched with the warfarin user 
group for all variables in the first 4 matches as well as 
anti-hypertensive treatment (diuretics, alpha-blocker, 
calcium channel blocker, ARB/ACE). Sixth, the NOAC 
user group were matched with the warfarin user group 
for all variables in the first 5 matches as well as differ-
ence in anti-diabetes treatments (insulin, metformin, 
sulfonylurea, thiazolidinediones, dipeptidyl peptidase-4 
inhibitors, sodium-glucose co-transporter-2 inhibitors, 
glucagon-like peptide 1). In each step of matching, we 
use coarsened exact matching (CEM) algorithm that 
is a monotonic imbalance reducing matching method, 
which means that the balance between the treated and 
control groups is chosen by ex ante user choice rather 
than discovered through the usual laborious process 
of “checking after the fact, tweaking the method, and 
repeatedly re-estimating” [17]. Patients both in the 
NOAC and warfarin user groups matched on step-6 
were retained (Fig. 1).
Via CEM we restricted the comparison of NOAC and 
warfarin user groups to areas of common support, i.e. 
sufficient overlap between the two groups, on the above 
key factors in the six-steps, coarsened using the default 
Sturges measure of bin size [18]. After excluding patients 
(Fig.  1) who were off common support, we then used 
entropy balancing [19] to efficiently minimise differences 
in the distribution of matching variables between NOAC 
and warfarin user groups. Entropy balancing involves 
maximum entropy reweighting the matched sample in 
each matching step to key target moments (mean, vari-
ance and skewness). For continuous matching variables, 
all three moments should be met; for binary variables the 
only target moment is the mean as it is only sufficient to 
match higher moments (variance and skewness).
Weighted logistic regression, incorporating matching 
weights estimated from each matching step by entropy 
matching, was applied in each matching step. This pro-
vided an estimate of the association between NOAC use 
and risk of hospitalisation mainly due to bleeding and 
CVD, with warfarin as the reference group [19].
Results
We identified 862 people with type 2 diabetes with inci-
dent NOAC prescription and 626 people with type 2 
diabetes with incident warfarin prescription between 
2017 and 2018 in the two CCGs. Table 1 and Fig. 2 dem-
onstrate that the matched variables were quite different 
between NOAC users and warfarin users. For example, 
NOAC users have a lower HbA1c with fewer existing 
bleeding or CVD comorbidities comparing with warfa-
rin users (Table 1). The distributions of outcomes in the 
unmatched cohorts and cohorts matched by coarsened 
exact matching are presented in Table 2.  
By coarsened exact matching, 528 incident NOAC 
users with type 2 diabetes were matched with 486 war-
farin users with type 2 diabetes via 6 matching steps 
(Fig.  1). After coarsened exact matching, the matched 
variables tended to be closer (Tables 1, 3, Fig. 2). In par-
ticular, matched variables were very similar after samples 
were weighted by entropy matching (Fig.  2, Additional 
file 1: Table S1) in terms of mean, variance and skewness.
Compared with warfarin users, NOAC users were asso-
ciated with increased risk of hospitalisation mainly due 
to bleeding (Fig. 3). The odds ratio weighted by matched 
variables in each matching step was 1.93 (95 confidence 
intervals 0.97–3.84) for model (i) weighted for age at inci-
dent anticoagulant prescription, gender, the CCG where 
their practices belonged, and duration of recorded diag-
nosed type 2 diabetes by their incident anticoagulant 
prescription; 2.14 (1.03–4.44) for model (ii) weighted for 
all adjusted variables in model (i) plus body mass index, 
systolic blood pressure, HbA1c and total cholesterol; 2.31 
(1.10–4.85) for model (iii) weighted for all adjusted vari-
ables in model (ii) plus prior bleeding (gastrointestinal 
bleeding and other bleeding) and CVD subtypes (hyper-
tension, atrial fibrillation, heart failure, ischemic heart 
disease, cerebrovascular diseases, valvular heart dis-
ease, venous thrombosis); 2.42 (1.14–5.14) for model (iv) 
weighted for all adjusted variables in model (iii) plus pre-
scriptions potentially relevant to bleeding event (antide-
pressant, Statin, NSAIDS, Corticosteroid, proton pump 
inhibitor for gastrointestinal disease, and antiplatelet); 
2.41 (1.12–5.18) for model (v) weighted for all adjusted 
variables in model (iv) plus anti-hypertensive treatment 
(diuretics, alpha-blocker, calcium channel blocker, ARB/
ACE); 2.51 (1.17–5.38) for model (vi) weighted for all 
adjusted variables in model (v) plus anti-diabetes treat-
ments (insulin, metformin, sulfonylurea, thiazolidinedi-
ones, dipeptidyl peptidase-4 inhibitors, sodium-glucose 
co-transporter-2 inhibitors, glucagon-like peptide 1).
Compared with warfarin users, NOAC users were not 
associated with a significant risk of hospitalisation due to 
CVD (Fig. 3). The weighted odds ratios were 1.17 (0.70–
1.94), 0.99 (0.58–1.70), 0.97 (0.56–1.69), 0.93 (0.53–1.62), 
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Table 1 Baseline characteristics in the comparison cohorts
CVD indicates cardiovascular diseases
Estimated glomerular filtration rate was presented as median (interquartile range)
a  Prior CVD or bleeding comorbidities include congestive cardiac failure, ischemic heart disease, stroke, valvular heart disease, venous thromboembolism, atrial 
fibrillation, hypertension, bleeding, and gastrointestinal bleeding
b  Prescriptions potentially correlating with bleeding/CVD include proton pump inhibitors for gastrointestinal disease, antiplatelet, antidepressant, corticosteroids, 
and statins
c  Anti-diabetes agents/insulin includes metformin, sulfonylurea, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, sodium-glucose contransporter-2 inhibitors, 
glucagon-like peptide 1, and alpha glucosidase inhibitor
d  Anti-hypertensive treatment includes diuretics, alpha-blocker, calcium channel blocker, ARB/ACE
Unmatched cohorts Cohorts after coarsened exact matching
Incident NOAC users 
(N = 862)
Incident warfarin 
users (N = 626)
P-value 
for matching 
variables
Incident NOAC users 
(N = 582)
Incident warfarin 
users (N = 486)
P-value 
for matching 
variables
Clinical commission group-2, n (%) 363 (42.1) 287 (45.9) 0.152 234 (44.3) 243 (50.0) 0.070
Age, years 75.8 (10.2) 73.3 (9.6) < 0.0001 75.4 (10.2) 74.2 (9.1) 0.066
Male Gender, n (%) 515 (59.7) 384 (61.3) 0.534 350 (66.3) 305 (62.8) 0.240
Duration of diabetes, years 5.5 (4.6) 6.4 (5.3) 0.001 6.1 (5.2) 5.2 (4.5) 0.004
Body mass index, kg/m2 31.9 (6.7) 32.5 (6.9) 0.090 31.9 (6.6) 32.1 (6.8) 0.647
Systolic blood pressure, mmHg 133 (13) 132 (13) 0.447 132 (13.1) 132 (12.4) 0.936
Total cholesterol, mmol/L 4.2 (1.1) 4.2 (1.0) 0.825 4.1 (1.0) 4.2 (1.0) 0.329
HbA1c, mmol/mol/% 54.7 (14.7) /7.2 (3.5) 58.0 (15.4)/7.5 (3.6) 0.702 57.3 (14.3)/7.4 (3.5) 56.8 (14.5)/7.3 (3.5) 0.606
Estimated glomerular filtration rate, 
mL/min/1.73m2
85 (82 to 90) 83 (78 to 90) 0.125 86 (83 to 90) 84 (79 to 90) 0.325
No of prior CVD or bleeding  comorbiditiesa
 0 28 (3.3) 45 (7.2) < 0.0001 19 (3.6) 34 (7.0) 0.824
 1 135 (15.7) 102 (16.3) 92 (17.4) 79 (16.3)
 2 235 (27.3) 190 (30.4) 153 (29.0) 153 (31.5)
 3 237 (27.5) 146 (23.3) 150 (28.4) 131 (27.0)
 4 140 (16.2) 91 (14.5) 100 (18.9) 75 (15.4)
 5 64 (7.4) 35 (15.6) 11 (2.1) 6 (1.2)
 6 19 (2.2) 14 (2.2) 3 (0.6) 7 (1.4)
 7 3 (0.4) 3 (0.5) 0 (0.0) 1 (0.2)
 8 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0)
No of prescriptions potentially correlating with bleeding/CVDb
 0 119 (13.8) 87 (13.9) 0.097 75 (14.2) 68 (14.0) 0.535
 1 189 (21.9) 176 (28.1) 135 (25.6) 149 (30.7)
 2 163 (18.9) 132 (21.1) 103 (19.5) 108 (22.2)
 3 197 (22.9) 131 (20.9) 118 (22.4) 103 (21.2)
 4 148 (17.2) 78 (12.5) 88 (16.7) 52 (10.7)
 5 45 (5.2) 21 (3.4) 9 (1.7) 5 (1.0)
 6 1 (0.1) 1 (0.2) 0 (0.0) 1 (0.2)
No of anti-diabetes agents/insulinc
 Diet 300 (34.8) 197 (31.5) 0.468 195 (36.9) 168 (34.6) 0.183
 1 313 (36.3) 246 (29.3) 198 (37.5) 207 (42.6)
 2 164 (19.0) 114 (18.2) 101 (19.1) 89 (18.3)
 3 73 (8.5) 56 (9.0) 29 (5.5) 17 (3.5)
 4 12 (1.4) 12 (1.9) 5 (1.0) 5 (1.0)
 5 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0)
No of anti-hypertensive  agentsd
 0 107 (12.4) 96 (15.3) 0.086 60 (11.4) 71 (14.6) 0.078
 1 199 (23.1) 112 (17.9) 130 (24.6) 89 (18.3)
 2 248 (28.8) 201 (32.1) 154 (29.2) 164 (33.7)
 3 219 (25.4) 163 (26.0) 126 (23.9) 120 (24.7)
 4 75 (8.7) 47 (7.5) 50 (9.5) 36 (7.4)
 5 14 (1.6) 7 (1.1) 8 (1.5) 6 (1.2)
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0.92 (0.53–1.61) and 0.94 (0.54–1.65) for model (i) to 
model (vi), respectively.
However, compared with warfarin users, NOAC users 
were associated with a higher risk of re-hospitalisation 
due to CVD (Fig.  3). The weighted odds ratios were 
2.21 (1.04–4.68), 2.13 (1.01–4.52), 2.47 (1.08–5.62), 2.46 
(1.02–5.94), 2.51 (1.01–6.20), and 2.66 (1.02–6.94) for 
model (i) to model (vi), respectively.
Discussion
Main findings
Based on routinely collected primary care electronic 
health records linked with hospitalisation data in a pop-
ulation with type 2 diabetes, we have, for the first time, 
identified an increased risk of hospitalisation due to 
bleeding events and re-hospitalisation due to CVD asso-
ciated with incident NOAC use compared with incident 
warfarin use. The risk of hospitalisation due to CVD did 
not significantly differ between incident NOAC and war-
farin users.
Strengths and limitations
A key strength of this work was the application of a 
novel, tapered matching method to form a ‘quasi-trial’ 
comparison sample to compare the risk of hospitalisa-
tion for the three outcomes between incident NOAC and 
warfarin users with type 2 diabetes. Through the tapered 
matching, we were able to transparently examine how 
differences in specific sets of confounders contributed 
to the risk of hospitalisation. By sequentially controlling 
for differences in demographic characteristics, clinical 
measurements, prior bleeding and CVD, prescriptions 
potentially relevant with bleeding, anti-hypertensive and 
anti-diabetes treatments, we observed how the risks of 
hospitalisation due to bleeding and CVD (re)hospitalisa-
tion compared after each match between new NOAC and 
the new warfarin users. This prospective cohort incor-
porating people with type 2 diabetes was derived from 
two independent primary care data bases in England 
that were linked with hospitalisation data. UK primary 
care electronic health records data (e.g. Clinical Practice 
Research Datalink) have been shown to be of good qual-
ity in terms of representativeness, coverage, validity, and 
consistency in records of comorbidities and prescriptions 
Table 2 The distribution of outcomes in the comparison cohorts
CVD indicates cardiovascular diseases
Unmatched cohorts Cohorts after coarsened exact matching
Incident NOAC users 
(N = 862)
Incident warfarin users 
(N = 626)
Incident NOAC users 
(N = 582)
Incident 
warfarin users 
(N = 486)
Hospitalisation mainly due to CVD, n (%) 190 (22.0) 63 (10.1) 91 (17.2) 44 (9.1)
Hospitalisation mainly due to bleeding, n (%) 50 (5.8) 33 (5.3) 25 (4.7) 18 (3.7)
Re-hospitalisation mainly due to CVD, n (%) 70 (8.1) 15 (2.4) 37 (7.0) 8 (1.7)
Fig. 2 Distribution of difference of means, variance and skewness on matched variables in the unmatched and matched cohorts. Triangles indicate 
measurements from unmatched cohorts; diamonds indicate measurements from coarsened exact matching; circles indicate measurements from 
entropy matching cohorts
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[20]. Hospitalisation data used in the study were com-
plete as SUS data captures all hospitalisation informa-
tion for patients and its recorded outcomes, which has 
also been proven to have good validity including those 
experiencing events outside of the CCG catchment [21]. 
There are some limitations in this study. First, as the sam-
ple size was restricted, instead of exactly matching each 
bleeding and CVD comorbidity, each anti-hypertensive 
prescription and each anti-diabetes prescription, we have 
matched the number of bleeding and CVD comorbidities, 
number of antihypertensive prescriptions and number of 
anti-diabetes prescriptions. However, we have compared 
the bleeding and CVD comorbidity, each antihyperten-
sive prescription, and each anti-diabetes prescription 
after matching, no significant difference was identified 
between NOAC and warfarin user groups (Table 3). The 
risks of three outcomes were also examined by number of 
CVD or bleeding comorbidities, number of prescriptions 
potentially correlating with bleeding or CVD and num-
ber of anti-hypertensive agents. Neither in the NOAC or 
warfarin cohorts, did patients with more comorbidities, 
more prescriptions or more anti-hypertensive agents 
have statistically different risks of outcomes, compared 
with patients with less comorbidities, less prescriptions 
or less anti-hypertensive agents. Second, the outcomes 
were short-term (within 12  months since the first anti-
coagulant prescription). The long-term risks of these 
outcomes need to be examined in external longer-term 
studies. Third, death linkage was not accessible in this 
study, therefore the competing risk from death could not 
be evaluated. Fourth, due to the restrictions in sample 
size, the comparison between each NOAC with warfarin 
could not be made.
Some biomarkers (e.g. von Willebrand factor, fibrin-
ogen and D-dimer) and prognostic factors of bleeding 
(Anti-IIa or anti-Xa levels) as potential matching vari-
ables were not available in the current study. Future 
replication studies with matching of these biomarkers 
are warranted.
Previous trials [22–29] and two meta-analysis [30, 
31] revealed non-difference or benefits of NOAC for 
diabetes patients with AF. This differs from our target 
Table 3 Bleeding/CVD subtypes, anti-hypertensive treatments, and  anti-diabetes treatments distribution 
in the unmatched and coarsened exact matched cohorts
Unmatched cohorts P-values Cohorts after coarsened exact 
matching
P-value
Incident NOAC 
users (N = 862)
Incident 
warfarin users 
(N = 626)
Incident NOAC 
users (N = 582)
Incident 
warfarin users 
(N = 486)
Prior CVD or bleeding comorbidities
 Atrial fibrillation, n (%) 622 (72.2) 386 (61.7) < 0.0001 383 (72.5) 349 (71.8) 0.530
 Heart failure, n (%) 159 (18.5) 109 (17.4) 0.601 72 (13.6) 77 (15.8) 0.321
 Cerebrovascular disease, n (%) 177 (20.5) 112 (17.9) 0.203 106 (20.1) 79 (16.3) 0.116
 Hypertension, n (%) 584 (67.8) 409 (65.3) 0.956 337 (63.8) 311 (64.0) 0.329
 Ischemic heart disease, n (%) 239 (27.7) 170 (27.2) 0.808 130 (24.6) 120 (24.7) 0.979
 Valvular heart disease, n (%) 70 (8.1) 71 (11.3) 0.036 36 (6.8) 45 (9.3) 0.152
 Venous thromboembolism, n (%) 78 (9.1) 68 (10.9) 0.246 39 (7.4) 46 (9.5) 0.233
 Prior bleeding, n (%) 382 (44.3) 219 (35.0) < 0.0001 202 (38.3) 163 (33.5) 0.118
 Gastrointestinal bleeding, n (%) 28 (3.3) 20 (3.2) 0.954 16 (3.0) 10 (2.1) 0.328
Anti-hypertensive treatment
 Diuretics, n (%) 365 (42.3) 252 (40.3) 0.420 215 (40.7) 190 (39.1) 0.598
 Beta-blocker, n (%) 450 (52.2) 338 (54.0) 0.495 280 (53.0) 267 (54.9) 0.543
 Calcium channel blockers, n (%) 314 (36.4) 186 (29.7) 0.006 162 (30.7) 149 (30.7) 0.427
 ARB/ACEi, n (%) 508 (58.9) 389 (62.1) 0.212 301 (57.0) 301 (61.9) 0.111
Anti-diabetes treatments
 Insulin, n (%) 122 (14.2) 97 (15.5) 0.471 63 (11.9) 64 (13.2) 0.552
 Metformin, n (%) 445 (51.6) 329 (52.6) 0.722 264 (50.0) 238 (49.0) 0.743
 Sulfonylurea, n (%) 171 (19.8) 133 (21.3) 0.506 92 (17.4) 84 (17.3) 0.953
 Thiazolidinediones, n (%) 12 (1.4) 16 (2.6) 0.103 5 (1.0) 6 (1.2) 0.659
 Dipeptidyl peptidase-4 inhibitors, n (%) 119 (13.8) 85 (13.6) 0.910 66 (12.5) 46 (9.5) 0.123
 Sodium-glucose co-transporter-2 inhibitors, n (%) 24 (2.8) 23 (3.7) 0.333 10 (1.9) 13 (2.7) 0.404
 Glucagon-like peptide 1, n (%) 12 (1.4) 12 (1.9) 0.428 6 (1.1) 5 (1.0) 0.869
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population which was the general type 2 diabetes popu-
lation. Unfortunately, it was not possible for this study 
to apply a matching procedure in the subgroup of dia-
betes with AF due to its sample size. Future replication 
studies among diabetes patients with AF are warranted.
As the study was aimed to evaluate the impact of 
persistent exposure of each anticoagulant, a study of 
intermittent users after the first 30 days of use (for any 
reason e.g. adherence, side effect) has not been able 
to be included. Future studies addressing the dose–
response relationship of time-varying exposure for each 
anticoagulant and outcomes are warranted.
Although some cases would have experienced 
switched anticoagulant prescriptions, the reasons for 
such a switch are not available and they might repre-
sent a specific anticoagulant user subgroup, The aim of 
the study was to compare the independent persistent 
exposure of NOAC and warfarin and in such a sub-
group, a wash-out period between the two anticoagu-
lants would be required, an unrealistic scenario in the 
routine primary care. Therefore, the risk from switch-
ing anticoagulant prescriptions should be evaluated in 
future studies.
INR information was not available in this study and 
INR monitoring and maintenance of a therapeutic/safe 
INR was seen as part of warfarin use (and one of the rea-
sons for using NOACs).
Comparison with prior studies
As NOACs do not require routine blood testing, they 
have been increasingly prescribed to replace the tradi-
tional anticoagulant, warfarin. Both observational studies 
and trials in the general population have suggested that 
NOACs are associated with less major bleeding events. 
Few studies, particularly cohort studies have explored 
differences between NOACs and warfarin among people 
with type 2 diabetes. In some trials, subgroup analyses 
have revealed heterogenous effects on bleeding among 
patients with diabetes. For example, in the ARISTO-
TLE trial [32] no difference in bleeding risk was shown 
between apixaban and warfarin in the group with diabe-
tes. In ENGAGE AF-TIMI 48 trial bleeding was reduced 
in patients both with, and without, diabetes for edoxaban. 
Furthermore, in a meta-analysis of data from the pivotal 
NOAC trials [33], the risks of major bleeding with NOAC 
vs warfarin in patients with vs without diabetes were 
not statistically different (interaction, P = 0.12). Using 
our well-designed tapered matching method, we have 
formed quasi-trial comparison samples able to compare 
patients with type 2 diabetes using either NOAC or war-
farin and revealed an increased risk of bleeding hospi-
talisation within 12 months after the initiation of NOAC 
comparing with warfarin. Moreover, we found there was 
no difference between NOAC and warfarin in terms of 
short-term risk of CVD hospitalisation; but increased 
Fig. 3 Adjusted odds ratios for association between NOAC (reference to warfarin) and risk of bleeding hospitalisation, CVD hospitalisation, 
CVD re-hospitalisation. Naive model weighted for age at incident anticoagulant prescription, gender, the CCG where their practices belong to, 
and duration of having recorded diagnosed type 2 diabetes by their incident anticoagulant prescription; model (i) weighted for all adjusted 
variables in model naïve model plus body mass index, systolic blood pressure, HbA1c and total cholesterol; model (ii) weighted for all adjusted 
variables in model (i) plus prior bleeding (gastrointestinal bleeding and other bleeding) and cardiovascular disease subtypes (hypertension, atrial 
fibrillation, heart failure, ischemic heart disease, cerebrovascular diseases, valvular heart disease, venous thrombosis); model (iii) weighted for all 
adjusted variables in model (ii) plus prescriptions potentially relevant to bleeding event (antidepressant, Statin, NSAIDS, Corticosteroid, proton 
pump inhibitor for gastrointestinal disease, and antiplatelet); model (iv) weighted for all adjusted variables in model (iii) plus anti-hypertensive 
treatment (diuretics, alpha-blocker, calcium channel blocker, ARB/ACE); model (v) weighted for all adjusted variables in model (iv) plus anti-diabetes 
treatments (insulin, metformin, sulfonylurea, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, 
glucagon-like peptide 1)
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risk of re-hospitalisation due to CVD within 12 months 
was observed in NOAC comparing with warfarin.
Clinical implications
Findings in this study, if confirmed, suggests that caution 
may be required when prescribing the newer anticoagu-
lants to patients with type 2 diabetes. This would mean 
continuation of the regular blood testing needed for war-
farin but not NOACs. Different from the general popu-
lation, the traditional anticoagulant warfarin might be 
safer than NOAC in terms of short-term risk of bleeding 
and CVD re-hospitalisation, both of which are associated 
with large health-costs [8]. Moreover, due the superiority 
of the tapered matching method, the impact of potential 
confounders on comparisons between NOAC and war-
farin have been revealed. It has been found that among 
people with a prior history of bleeding or CVD, NOAC 
use would potentially increase the bleeding short-term 
risk of bleeding and CVD re-hospitalisation. Therefore, 
it might be wiser to prescribe warfarin for patients with 
type 2 diabetes and a prior history of bleeding or CVD. 
As we were limited by sample size, subgroups of patients 
with bleeding and those with prior CVD could not be 
analysed separately. Replication studies using other data 
are warranted.
Although a significant difference in risk of CVD hos-
pitalisation was not identified in the current study, the 
significant risk of CVD re-hospitalisation was found in 
NOAC users, suggesting the association between NOAC 
and the risk of severe CVD condition as the severe CVD 
condition would be more likely to trigger CVD re-hospi-
talisation. Unfortunately, as a result of the limited sam-
ple size, the subtype of CVD events could not be further 
evaluated in the current study.
Conclusion
Based on primary care data linked with hospitalisation 
data, via a novel tapered matching method, we formed 
‘quasi-trial’ comparison cohorts for incident NOAC and 
warfarin users with type 2 diabetes. This study showed an 
increased short-term risk of major bleeding hospitalisa-
tion, and of CVD re-hospitalisation in new NOAC users 
comparing with new warfarin users. For patients with 
type 2 diabetes, caution is warranted when prescribing 
NOACs as the first anticoagulant treatment, particu-
larly among patients with prior bleeding or a CVD his-
tory. Further large-scale replication studies in external 
datasets and replication studies with long-term outcomes 
and matching other possible confounders are warranted. 
Future comparative studies between subtypes of NOAC 
and warfarin, along with the development of specific 
risk algorithms for bleeding and CVD events in diabetes 
patients are also warranted.
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